Research programme: bispecific antibodies - Amgen

Drug Profile

Research programme: bispecific antibodies - Amgen

Alternative Names: AMG 596; AMG CDH19X

Latest Information Update: 28 Dec 2016

Price : $50

At a glance

  • Originator Micromet Inc
  • Developer Amgen
  • Class Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 29 Nov 2016 Pharmacodynamics data from a preclinical study presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2016)
  • 16 Apr 2016 Pharmacokinetic and pharmacodynamic data presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016) ,
  • 16 Apr 2016 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top